Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Prostate Cancer Market by Type (Hormone sensitive prostate cancer, Hormone refractory prostate cancer) and by Therapy (Chemotherapy, Hormonal Therapy, Targeted Therapy, Immunotherapy): Global Opportunity Analysis and Industry Forecast, 2023-2032

A01131

Pages: NA

Charts: NA

Tables: NA

The global prostate cancer market is poised to grow at an exponential pace, primarily due to the mounting prevalence of prostate cancer, rapidly aging population and strong bolstering pipeline. The market would undergo a transformation during the analysis period, attributed by emerging product launches and line extensions opted for existing therapies. Limited treatment options along with a booming patient pool has generated the need for novel effective therapies with enhanced survival benefits and minimal adverse effects.

Enhanced diagnosis and incidence rates in developed economies largely drive the market growth. In addition, strong emerging pipeline, improved R&D investment by drug innovators and increasing awareness would further boost the market growth. Conversely, uncertain reimbursement policies and the high cost incurred due to combination therapies and prolonged treatment durations are expected to curtail the market growth.

The unmet medical need for complete treatment would provide lucrative growth opportunities for innovators to address the untapped market potential in future. Furthermore, developing regions with rapid urbanization, sedentary lifestyle, rising awareness and improving healthcare access would offer attractive opportunities for innovators.

As the market mainly depends on improved overall survival, managing the drug lifecycle would be a key challenge for innovators to sustain in the prostate cancer market. Further, looming patent cliffs of leading drugs such as Zytiga, would translate into an opportunity for new entrants.
Few of the key strategies adopted by leading players in the market are new product launch and acquisitions. In August 2013, Johnson and Johnson acquired Aragon Pharmaceuticals (developing the late-stage prostate cancer molecule, ARN-509). Recently, Astellas in collaboration with Medivation launched Xtandi in various countries for the treatment of metastatic CRPC.

The report fragments the prostate cancer market on the basis of cancer type, therapy type and geography. Based on cancer type, the market is segmented into hormone sensitive prostate cancer and hormone refractory prostate cancer. Based on therapy type, the market is further segmented into chemotherapy, hormonal therapy, targeted therapy and immunotherapy. The report covers a geographic breakdown and a detailed analysis of each of the aforesaid segments across North America, Europe, Asia Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Astellas, Inc., AstraZeneca plc, Johnson & Johnson, Sanofi S.A, Bristol Myers Squibb (BMS), Bayer AG, and others are also provided in the report.

KEY MARKET BENEFITS:

  • A comprehensive analysis helps to identify the key market trends and dynamics in the global Prostate Cancer market
  • Extensive research is done for the market by therapy type which instils a clear understanding regarding the currently used hormonal therapy and targeted therapy drugs, evolving role of immunotherapies and in-line extensions opted for existing drugs
  • The studies evaluating competitive landscape and value chain has been taken into account in this report to help in understanding the competitive environment across the geographies
  • The prostate cancer market scenario is comprehensively analyzed in accordance with the key regions
  • The report covers the detailed quantitative analysis of the current market and estimations which would enable the stakeholders to capitalize on prevailing market opportunities
  • Owing to an emerging pipeline in the prostate cancer market, clinical studies have also been taken into account to better understand the market potential and opportunities
  • Competitive intelligence highlights the business practises followed by leading market players across geographies
  • A detailed SWOT analysis enables to study the internal environment of the leading companies for strategy formulation

 Key Market Segments

  • By Type
    • Hormone sensitive prostate cancer
    • Hormone refractory prostate cancer
  • By Therapy
    • Chemotherapy
      • Cytotoxic drugs
    • Hormonal Therapy
      • Anti-Androgens
      • LHRH Antagonists
      • LHRH Analogs
    • Targeted Therapy
      • Apoptosis inducing drugs
      • Angiogenesis inhibitor
      • Signal transduction inhibitor
    • Immunotherapy
      • Vaccines
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • AbbVie Inc
  • Bayer AG,
  • Bristol Myers Squibb (BMS)
  • Sanofi S.A
  • Johnson & Johnson
  • Sanofi
  • Ipsen Pharma
  • Astellas Pharma Inc
  • AstraZeneca plc
  • Astellas, Inc.,

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: PROSTATE CANCER MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Hormone Sensitive Prostate Cancer

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Hormone Refractory Prostate Cancer

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: PROSTATE CANCER MARKET, BY THERAPY

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Therapy

    • 5.2. Chemotherapy

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

      • 5.2.4. Cytotoxic drugs

        • 5.2.4.1. Market Size and Forecast

    • 5.3. Hormonal Therapy

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

      • 5.3.4. Anti-Androgens

        • 5.3.4.1. Market Size and Forecast

      • 5.3.4. LHRH Antagonists

        • 5.3.4.1. Market Size and Forecast

      • 5.3.4. LHRH Analogs

        • 5.3.4.1. Market Size and Forecast

    • 5.4. Targeted Therapy

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

      • 5.4.4. Apoptosis inducing drugs

        • 5.4.4.1. Market Size and Forecast

      • 5.4.4. Angiogenesis inhibitor

        • 5.4.4.1. Market Size and Forecast

      • 5.4.4. Signal transduction inhibitor

        • 5.4.4.1. Market Size and Forecast

    • 5.5. Immunotherapy

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

      • 5.5.4. Vaccines

        • 5.5.4.1. Market Size and Forecast

  • CHAPTER 6: PROSTATE CANCER MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Type

      • 6.2.3. Market Size and Forecast, By Therapy

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Prostate Cancer Market

        • 6.2.5.1. Market Size and Forecast, By Type
        • 6.2.5.2. Market Size and Forecast, By Therapy

      • 6.2.6. Canada Prostate Cancer Market

        • 6.2.6.1. Market Size and Forecast, By Type
        • 6.2.6.2. Market Size and Forecast, By Therapy

      • 6.2.7. Mexico Prostate Cancer Market

        • 6.2.7.1. Market Size and Forecast, By Type
        • 6.2.7.2. Market Size and Forecast, By Therapy

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Type

      • 6.3.3. Market Size and Forecast, By Therapy

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Prostate Cancer Market

        • 6.3.5.1. Market Size and Forecast, By Type
        • 6.3.5.2. Market Size and Forecast, By Therapy

      • 6.3.6. Germany Prostate Cancer Market

        • 6.3.6.1. Market Size and Forecast, By Type
        • 6.3.6.2. Market Size and Forecast, By Therapy

      • 6.3.7. Italy Prostate Cancer Market

        • 6.3.7.1. Market Size and Forecast, By Type
        • 6.3.7.2. Market Size and Forecast, By Therapy

      • 6.3.8. Spain Prostate Cancer Market

        • 6.3.8.1. Market Size and Forecast, By Type
        • 6.3.8.2. Market Size and Forecast, By Therapy

      • 6.3.9. UK Prostate Cancer Market

        • 6.3.9.1. Market Size and Forecast, By Type
        • 6.3.9.2. Market Size and Forecast, By Therapy

      • 6.3.10. Russia Prostate Cancer Market

        • 6.3.10.1. Market Size and Forecast, By Type
        • 6.3.10.2. Market Size and Forecast, By Therapy

      • 6.3.11. Rest Of Europe Prostate Cancer Market

        • 6.3.11.1. Market Size and Forecast, By Type
        • 6.3.11.2. Market Size and Forecast, By Therapy

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Type

      • 6.4.3. Market Size and Forecast, By Therapy

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Prostate Cancer Market

        • 6.4.5.1. Market Size and Forecast, By Type
        • 6.4.5.2. Market Size and Forecast, By Therapy

      • 6.4.6. Japan Prostate Cancer Market

        • 6.4.6.1. Market Size and Forecast, By Type
        • 6.4.6.2. Market Size and Forecast, By Therapy

      • 6.4.7. India Prostate Cancer Market

        • 6.4.7.1. Market Size and Forecast, By Type
        • 6.4.7.2. Market Size and Forecast, By Therapy

      • 6.4.8. South Korea Prostate Cancer Market

        • 6.4.8.1. Market Size and Forecast, By Type
        • 6.4.8.2. Market Size and Forecast, By Therapy

      • 6.4.9. Australia Prostate Cancer Market

        • 6.4.9.1. Market Size and Forecast, By Type
        • 6.4.9.2. Market Size and Forecast, By Therapy

      • 6.4.10. Thailand Prostate Cancer Market

        • 6.4.10.1. Market Size and Forecast, By Type
        • 6.4.10.2. Market Size and Forecast, By Therapy

      • 6.4.11. Malaysia Prostate Cancer Market

        • 6.4.11.1. Market Size and Forecast, By Type
        • 6.4.11.2. Market Size and Forecast, By Therapy

      • 6.4.12. Indonesia Prostate Cancer Market

        • 6.4.12.1. Market Size and Forecast, By Type
        • 6.4.12.2. Market Size and Forecast, By Therapy

      • 6.4.13. Rest of Asia Pacific Prostate Cancer Market

        • 6.4.13.1. Market Size and Forecast, By Type
        • 6.4.13.2. Market Size and Forecast, By Therapy

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Type

      • 6.5.3. Market Size and Forecast, By Therapy

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Prostate Cancer Market

        • 6.5.5.1. Market Size and Forecast, By Type
        • 6.5.5.2. Market Size and Forecast, By Therapy

      • 6.5.6. South Africa Prostate Cancer Market

        • 6.5.6.1. Market Size and Forecast, By Type
        • 6.5.6.2. Market Size and Forecast, By Therapy

      • 6.5.7. Saudi Arabia Prostate Cancer Market

        • 6.5.7.1. Market Size and Forecast, By Type
        • 6.5.7.2. Market Size and Forecast, By Therapy

      • 6.5.8. UAE Prostate Cancer Market

        • 6.5.8.1. Market Size and Forecast, By Type
        • 6.5.8.2. Market Size and Forecast, By Therapy

      • 6.5.9. Argentina Prostate Cancer Market

        • 6.5.9.1. Market Size and Forecast, By Type
        • 6.5.9.2. Market Size and Forecast, By Therapy

      • 6.5.10. Rest of LAMEA Prostate Cancer Market

        • 6.5.10.1. Market Size and Forecast, By Type
        • 6.5.10.2. Market Size and Forecast, By Therapy

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Astellas, Inc.,

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. AstraZeneca Plc

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Johnson And Johnson

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Sanofi S.A

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Bristol Myers Squibb (BMS)

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Bayer AG,

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Astellas Pharma Inc

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Ipsen Pharma

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Sanofi

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. AbbVie Inc

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL PROSTATE CANCER MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL PROSTATE CANCER MARKET FOR HORMONE SENSITIVE PROSTATE CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL PROSTATE CANCER MARKET FOR HORMONE REFRACTORY PROSTATE CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL PROSTATE CANCER MARKET, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL PROSTATE CANCER MARKET FOR CHEMOTHERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL PROSTATE CANCER MARKET FOR HORMONAL THERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL PROSTATE CANCER MARKET FOR TARGETED THERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL PROSTATE CANCER MARKET FOR IMMUNOTHERAPY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL PROSTATE CANCER MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. NORTH AMERICA PROSTATE CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. NORTH AMERICA PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 13. U.S. PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 14. U.S. PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 15. CANADA PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 16. CANADA PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 17. MEXICO PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 18. MEXICO PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 19. EUROPE PROSTATE CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. EUROPE PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 22. FRANCE PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 23. FRANCE PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 24. GERMANY PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 25. GERMANY PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 26. ITALY PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 27. ITALY PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 28. SPAIN PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 29. SPAIN PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 30. UK PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 31. UK PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 32. RUSSIA PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 33. RUSSIA PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 34. REST OF EUROPE PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 35. REST OF EUROPE PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 36. ASIA-PACIFIC PROSTATE CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 37. ASIA-PACIFIC PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 39. CHINA PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 40. CHINA PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 41. JAPAN PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 42. JAPAN PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 43. INDIA PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 44. INDIA PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 45. SOUTH KOREA PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 46. SOUTH KOREA PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 47. AUSTRALIA PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 48. AUSTRALIA PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 49. THAILAND PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 50. THAILAND PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 51. MALAYSIA PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 52. MALAYSIA PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 53. INDONESIA PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 54. INDONESIA PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 57. LAMEA PROSTATE CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 58. LAMEA PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 60. BRAZIL PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 61. BRAZIL PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 62. SOUTH AFRICA PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 63. SOUTH AFRICA PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 64. SAUDI ARABIA PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 65. SAUDI ARABIA PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 66. UAE PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 67. UAE PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 68. ARGENTINA PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 69. ARGENTINA PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 70. REST OF LAMEA PROSTATE CANCER, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 71. REST OF LAMEA PROSTATE CANCER, BY THERAPY, 2025-2033 ($MILLION)
  • TABLE 72. ASTELLAS, INC.,: KEY EXECUTIVES
  • TABLE 73. ASTELLAS, INC.,: COMPANY SNAPSHOT
  • TABLE 74. ASTELLAS, INC.,: OPERATING SEGMENTS
  • TABLE 75. ASTELLAS, INC.,: PRODUCT PORTFOLIO
  • TABLE 76. ASTELLAS, INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 77. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 78. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 79. ASTRAZENECA PLC: OPERATING SEGMENTS
  • TABLE 80. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 81. ASTRAZENECA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 82. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 83. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 84. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 85. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 86. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 87. SANOFI S.A: KEY EXECUTIVES
  • TABLE 88. SANOFI S.A: COMPANY SNAPSHOT
  • TABLE 89. SANOFI S.A: OPERATING SEGMENTS
  • TABLE 90. SANOFI S.A: PRODUCT PORTFOLIO
  • TABLE 91. SANOFI S.A: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 92. BRISTOL MYERS SQUIBB (BMS): KEY EXECUTIVES
  • TABLE 93. BRISTOL MYERS SQUIBB (BMS): COMPANY SNAPSHOT
  • TABLE 94. BRISTOL MYERS SQUIBB (BMS): OPERATING SEGMENTS
  • TABLE 95. BRISTOL MYERS SQUIBB (BMS): PRODUCT PORTFOLIO
  • TABLE 96. BRISTOL MYERS SQUIBB (BMS): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97. BAYER AG,: KEY EXECUTIVES
  • TABLE 98. BAYER AG,: COMPANY SNAPSHOT
  • TABLE 99. BAYER AG,: OPERATING SEGMENTS
  • TABLE 100. BAYER AG,: PRODUCT PORTFOLIO
  • TABLE 101. BAYER AG,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 102. ASTELLAS PHARMA INC: KEY EXECUTIVES
  • TABLE 103. ASTELLAS PHARMA INC: COMPANY SNAPSHOT
  • TABLE 104. ASTELLAS PHARMA INC: OPERATING SEGMENTS
  • TABLE 105. ASTELLAS PHARMA INC: PRODUCT PORTFOLIO
  • TABLE 106. ASTELLAS PHARMA INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107. IPSEN PHARMA: KEY EXECUTIVES
  • TABLE 108. IPSEN PHARMA: COMPANY SNAPSHOT
  • TABLE 109. IPSEN PHARMA: OPERATING SEGMENTS
  • TABLE 110. IPSEN PHARMA: PRODUCT PORTFOLIO
  • TABLE 111. IPSEN PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. SANOFI: KEY EXECUTIVES
  • TABLE 113. SANOFI: COMPANY SNAPSHOT
  • TABLE 114. SANOFI: OPERATING SEGMENTS
  • TABLE 115. SANOFI: PRODUCT PORTFOLIO
  • TABLE 116. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. ABBVIE INC: KEY EXECUTIVES
  • TABLE 118. ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 119. ABBVIE INC: OPERATING SEGMENTS
  • TABLE 120. ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 121. ABBVIE INC: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL PROSTATE CANCER MARKET SEGMENTATION
  • FIGURE 2. GLOBAL PROSTATE CANCER MARKET
  • FIGURE 3. SEGMENTATION PROSTATE CANCER MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN PROSTATE CANCER MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALPROSTATE CANCER MARKET
  • FIGURE 11. PROSTATE CANCER MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. PROSTATE CANCER MARKET FOR HORMONE SENSITIVE PROSTATE CANCER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. PROSTATE CANCER MARKET FOR HORMONE REFRACTORY PROSTATE CANCER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. PROSTATE CANCER MARKET SEGMENTATION, BY BY THERAPY
  • FIGURE 15. PROSTATE CANCER MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. PROSTATE CANCER MARKET FOR HORMONAL THERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. PROSTATE CANCER MARKET FOR TARGETED THERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. PROSTATE CANCER MARKET FOR IMMUNOTHERAPY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 20. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 21. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 22. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 23. COMPETITIVE DASHBOARD
  • FIGURE 24. COMPETITIVE HEATMAP: PROSTATE CANCER MARKET
  • FIGURE 25. TOP PLAYER POSITIONING, 2024
  • FIGURE 26. ASTELLAS, INC.,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 27. ASTELLAS, INC.,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 28. ASTELLAS, INC.,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 29. ASTRAZENECA PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 30. ASTRAZENECA PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 31. ASTRAZENECA PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 32. JOHNSON AND JOHNSON: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. SANOFI S.A: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. SANOFI S.A: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. SANOFI S.A: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. BRISTOL MYERS SQUIBB (BMS): NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. BRISTOL MYERS SQUIBB (BMS): REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. BRISTOL MYERS SQUIBB (BMS): REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. BAYER AG,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. BAYER AG,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. BAYER AG,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. ASTELLAS PHARMA INC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. ASTELLAS PHARMA INC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. ASTELLAS PHARMA INC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. IPSEN PHARMA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. IPSEN PHARMA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. IPSEN PHARMA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. SANOFI: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. SANOFI: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. SANOFI: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. ABBVIE INC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. ABBVIE INC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. ABBVIE INC: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Prostate Cancer Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved